Historique de carrière de John Yates
Anciens postes connus de John Yates
Sociétés | Poste | Début | Fin |
---|---|---|---|
ARRAY TECHNOLOGIES, INC. | Directeur Technique/Scientifique/R&D | 01/05/2007 | 15/09/2008 |
Takeda Global Research & Development Center, Inc. | President | 01/01/2004 | 01/01/2007 |
MERCK & CO., INC. | Directeur Technique/Scientifique/R&D | 01/01/1990 | 01/01/2003 |
RADIUS HEALTH, INC. | Directeur Technique/Scientifique/R&D | 09/01/2014 | - |
Formation de John Yates
The University of Sheffield | Doctorate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Royaume-Uni | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 3 |
President | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Takeda Global Research & Development Center, Inc. |
- Bourse
- Insiders
- John Yates
- Expérience